Abstract | BACKGROUND: Thyroid tumor is the most common malignant cancer of endocrinology, with an increasing incidence in the world. In the absence of specific markers of malignancy, it is a real challenge to distinguish benign and malignant thyroid tumors under the microscope. METHODS: RESULTS: Statistically, it was clearly found that all three markers should be used in a panel, not only distinguishing malignant and benign thyroid tumors but also differentiating follicular carcinoma from papillary carcinoma. It also confirmed previous observations that Galectin-3 alone is highly sensitive for papillary carcinoma but not adequately sensitive for follicular carcinoma. CONCLUSIONS: PTTG alone is not adequately sensitive for the evaluation of any thyroid lesion. The combination of Galectin-3 and PTTG is complementary as a diagnostic biomarker for patients with papillary carcinoma.
|
Authors | Wenli Cui, Xiaomei Lu, Shutao Zheng, Yuqing Ma, Xia Liu, Wei Zhang |
Journal | Clinical laboratory
(Clin Lab)
Vol. 58
Issue 5-6
Pg. 419-26
( 2012)
ISSN: 1433-6510 [Print] Germany |
PMID | 22783570
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Galectin 3
- Ki-67 Antigen
- Neoplasm Proteins
- Securin
- pituitary tumor-transforming protein 1, human
|
Topics |
- Adenocarcinoma, Follicular
(diagnosis, metabolism)
- Adenocarcinoma, Papillary
(diagnosis, metabolism)
- Adenoma
(diagnosis, metabolism)
- Biomarkers, Tumor
(metabolism)
- Galectin 3
(metabolism)
- Humans
- Immunoenzyme Techniques
- Ki-67 Antigen
(metabolism)
- Neoplasm Proteins
(metabolism)
- Securin
- Thyroid Gland
(metabolism)
- Thyroid Neoplasms
(diagnosis, metabolism)
|